Global NGS based RNA seq Market Size By Type (SBS, SMRT), By Application (Transcriptome Epigenetics, Small RNA), By Region, And Segment Forecasts, 2023 to 2032

The Global NGS-based RNA Sequencing (RNA-Seq) Market was valued at USD 2.9 billion in 2023 and is projected to reach USD 9.4 billion by 2031, growing at a CAGR of 15.8% during the forecast period from 2023 to 2031. The increasing adoption of next-generation sequencing technologies in transcriptomics, the rising demand for personalized medicine, and the ongoing advancements in bioinformatics tools are driving market growth. RNA-Seq provides high-resolution insights into gene expression patterns, making it an essential tool for disease diagnostics, drug discovery, and biomarker development.

Drivers:

1. Rising Demand for Precision Medicine and Cancer Genomics

RNA-Seq is pivotal in precision medicine by enabling comprehensive transcriptomic profiling. The ability to identify novel transcripts, gene fusions, and alternative splicing events is particularly important in oncology, boosting adoption across cancer research and clinical diagnostics.

2. Technological Advancements in Sequencing Platforms

Continuous innovations in sequencing platforms—such as single-cell RNA sequencing and long-read RNA-Seq—are improving accuracy, throughput, and cost-efficiency. These advancements are expanding the applications of RNA-Seq in both research and clinical settings.

3. Surge in Government Funding and Research Initiatives

Numerous national and international initiatives are promoting genomics research through funding and infrastructure support, especially in developed countries. This trend is positively impacting RNA-Seq technology adoption across academic and clinical laboratories.

Restraints:

1. High Cost of Sequencing and Data Analysis Infrastructure

Despite cost reductions, comprehensive RNA-Seq studies, especially single-cell and full-transcriptome projects, remain expensive. The need for sophisticated equipment and computational infrastructure poses challenges for small and medium-sized labs.

2. Data Interpretation Complexity

The generation of massive amounts of data requires advanced bioinformatics skills. Limited access to skilled professionals and standardized data interpretation protocols can hinder accurate analysis and slow down adoption.

Opportunity:

1. Expanding Applications in Infectious Disease and Immune Profiling

RNA-Seq is being increasingly applied in virology, immunology, and pandemic research. Profiling host-pathogen interactions and immune responses offers new avenues for therapeutic development and vaccine efficacy studies.

2. Growth in Emerging Markets and CRO Partnerships

Countries in Asia-Pacific and Latin America are increasing their investments in genomics and molecular diagnostics. Coupled with the rise of contract research organizations (CROs) offering cost-effective sequencing services, the market is set to gain significant momentum.

Market by System Type Insights:

In 2023, Whole Transcriptome RNA-Seq dominated the system type segment due to its broad applicability in gene expression profiling and novel transcript discovery. However, Single-cell RNA-Seq is expected to witness the fastest growth rate over the forecast period. This surge is attributed to its transformative potential in cell-level resolution studies, crucial for understanding tumor heterogeneity and stem cell biology.

Market by End-use Insights:

The Academic & Research Institutions segment held the largest share in 2023, driven by high volumes of basic and translational research. Increasing collaborations between academia and pharmaceutical firms are further boosting this segment. The Clinical Diagnostics segment is poised for rapid growth, propelled by the clinical integration of RNA-Seq in oncology, neurology, and infectious disease diagnostics.

Market by Regional Insights:

North America led the global market in 2023, underpinned by strong R&D infrastructure, supportive government funding, and the presence of key industry players. Asia-Pacific is expected to witness the highest growth rate during the forecast period, fueled by growing investments in genomics, an expanding biotech sector, and increasing focus on personalized medicine in countries like China and India.

Competitive Scenario:

Key players operating in the Global NGS-based RNA Seq Market include Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics, Pacific Biosciences of California, Inc., Agilent Technologies, QIAGEN N.V., Oxford Nanopore Technologies Ltd., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, and PerkinElmer Inc. These companies are focusing on strategic collaborations, product innovations, and regional expansion to strengthen their market presence.

Scope of Work – Global NGS-based RNA Seq Market

Report Metric Details

Market Size (2023) USD 2.9 billion

Projected Market Size (2031) USD 9.4 billion

CAGR (2023–2031) 15.8%

Market Segments By System Type (Whole Transcriptome, Single-cell RNA-Seq), By End-use (Research, Clinical Diagnostics)

Growth Drivers Rising demand for precision medicine, cancer genomics, government R&D investments

Opportunities Expanding use in infectious disease research, growth in emerging markets

Key Market Developments:

2023: Illumina, Inc. launched its latest RNA library preparation kit optimized for single-cell and low-input samples to accelerate personalized therapy research.

2024: Thermo Fisher Scientific entered a strategic alliance with a leading hospital chain to implement RNA-Seq in clinical oncology diagnostics across North America.

2025: BGI Genomics introduced a cloud-based data analytics platform integrated with AI for real-time transcriptome analysis, enhancing scalability for CROs and researchers.

FAQs:

1) What is the current market size of the Global NGS-based RNA Seq Market?

The market size was valued at USD 2.9 billion in 2023.

2) What is the major growth driver of the Global NGS-based RNA Seq Market?

The primary driver is the rising demand for precision medicine and advancements in cancer genomics.

3) Which is the largest region during the forecast period in the Global NGS-based RNA Seq Market?

North America is the largest region due to its strong infrastructure and funding support.

4) Which segment accounted for the largest market share in the Global NGS-based RNA Seq Market?

The Whole Transcriptome RNA-Seq segment led the market in 2023.

5) Who are the key market players in the Global NGS-based RNA Seq Market?

Key players include Illumina, Thermo Fisher Scientific, BGI Genomics, Agilent Technologies, and QIAGEN.